Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Table 1 Characteristics of eligible trials in the meta-analysis

Trial	Year	Median age(LD)	Median age(D)	Tumor type	Total	Number of patients LD D		Control arm drug	Dose of anthracyclines	Liposomal anthracyclines
Gill et al. [22]	1996	37	37	AIDS-KS	232	116	111	Doxorubicin	L dauno-40 mg/m2 Doxo-10 mg/m2	Lipo- Dauno
Northfelt et al. [23]	1998	36	38	AIDS-KS	258	133	125	Doxorubicin	PLD-20 mg/m2 D-20 mg/m2	PLD
Judson et al. [24]	2000	52	52	Metastatic soft tissue sarcoma	94	50	44	Doxorubicin	PLD-50 mg/m2 D- 75 mg/m2	PLD (CAELYX)
Harris et al. [8]	2001	58	58	MBC	224	108	116	Doxorubicin	LED- 75 mg Doxorubicin- 75 mg/m2	Myocet
Batist et al. [16]	2001	55	54	MBC	297	142	155	Doxorubicin	LED-60 mg/m2 Doxo-60 mg/m2	Myocet
O’Brien et al. [14]	2003	59	58	MBC	509	254	255	Doxorubicin	PLD-50 mg/m2 D- 60 mg/m2	PLD
Dimopoulos et al. [25]	2003	66	65	MM	259	132	127	Doxorubicin	doxil-40 mg doxo-9 mg/m2	Doxil bolus
Chan et al. [26]	2004	54	54	MBC	160	80	80	Epirubicin	LD-75 mg/m2 D-75 mg/m2	Myocet
Rifkin et al. [27]	2005	60	60	MM	192	97	95	Doxorubicin	Doxil-40 mg Doxo-9 mg/m2	Doxil

Abbreviations:AIDS-KS: Acquired immune deficiency syndrome- Kaposi Sarcoma; D: Doxorubicin; LD: Liposomal Doxorubicin; L Dauno: Liposomal Daunorubicin; MBC: Metastatic Breast Cancer; MM: Multiple Myeloma; PLD: Pegylated Liposomal Doxorubicin.

ISSN: 2162-3619